



EMIF Deliverable 5.2: Identify novel biomarkers of risk in extreme phenotypes which exhibit adequate sensitivity and specificity

Executive summary

Executive Summary

Deliverable 5.2 has identified a set of novel biomarkers for obesity –associated insulin resistance (mannose, CCL18 and S100A4) which are to be validated in larger cohorts within WP6 and -7. The identification of these biomarkers was based on analyses of adipose tissue gene expression and DNA-methylation in obese subjects discordant for insulin sensitivity as well as metabolomics analyses from plasma of obese subjects with different degrees of cardiometabolic complications. We have identified these novel biomarkers of risk in extreme phenotypes to exhibit adequate sensitivity and specificity

Contacts

EMIF-MET: Mikael Ryden
Mikael.Ryden@ki.se